Information letter to healthcare professionals regarding the medicinal product VINITEL® (valproate), syrup, 200 mg/5 ml “New measures regarding the potential risk of neurodevelopmental disorders in children born to men who took valproates (valproate) during the 3 months before conception.”

23.12.2024 846 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу ВІНІТЕЛ® (вальпроат), сироп, 200 мг/5мл «Нові заходи щодо потенційного ризику порушень нервовопсихічного розвитку у дітей, народжених від чоловіків, які приймали вальпроати (valproate) протягом 3 місяців до зачаття».PDF · 229 КБ

Завантажити

Information letter to healthcare professionals regarding the medicinal product VINITEL® (valproate), syrup, 200 mg/5 ml “New measures regarding the potential risk of neurodevelopmental disorders in children born to men who took valproates (valproate) during the 3 months before conception.”

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product VINITEL® (valproate), syrup, 200 mg/5 ml “New measures regarding the potential risk of neurodevelopmental disorders in children born to men who took valproates (valproate) during the 3 months before conception.”

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration